← Leaderboards
Michael Kaytor
Humanetics Corporation
$6,012,882
Attributed
$6,012,882
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2014–21$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,012,882 · 2
By mechanism
N01$4,513,701 · 1
N44$1,499,181 · 1
Top collaborators
No co-investigators on record.
Most similar at Humanetics Corporation
Same institution · by research overlap
- Isabel Lauren Jackson$7,555,426
- Michael D Kaytor$2,888,484
- John L. Zenk$600,000
- John Dykstra$3,606,440
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungRadiation TherapyAntioxidantsOralRadiationGenisteinPulmonary InflammationPulmonary FibrosisQuality Of LifeClinicMediatingPhase Ii TrialCovid-19Pulmonary FunctionMedical Center2019-NcovEfficacy TestingLung InjuryCancer PatientChestHospitalsImpairmentDiagnostic Radiologic ExaminationInjury
Grant awards (3)
SUPPLEMENTAL WORK-SARS-COV-2$1,872,652
N01 · FY2021 · AI · contact PI
SUPPLEMENTAL WORK-SARS-COV-2$2,641,049
N01 · FY2020 · AI · contact PI
EXERCISE PHASE II TITLE: DEVELOPMENT OF BIO 300 AS A RADIATION MODULATOR FOR USE DURING RADIOTHERAPY OF LUNG CANCER ; PERIOD OF PERFORMANCE FROM 09/20/2012 TO 01/09/2016DUNS: 197085517CAN8478361$1,499,181
N44 · FY2014 · CA · contact PI